NowoTrade

TRLV

TRLV Trulieve Cannabis Corp.

Stock · NYSE · United States · Healthcare · US89790E1064

NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Trulieve Cannabis Corp., and has no access to any account you may have with it. The name and the logo belong to their owners.

Price 11.56 USD +6.06%
52-week range 4.62 – 13.28
Dividend yield—
Market cap2.0B
NowoTrade score 33 Grade A

Price history

Daily prices in USD.

Updated 08 Nov 2026 14:26. Information, not advice.

Results

Next results 25 Feb 2027 in 109 days · 08:00 · estimate 0.12
Last results 0.09 vs 0.07 estimated 05 Nov 2026 · Beat +28.6%
Beat the estimate 11 of 12 1 missed · 0 in line · 4 beats in a row
Average surprise +82.9% reported against the estimate, last 12 quarters

Earnings per share: estimate and reported

09 Nov 2023: estimate -0.15 09 Nov 2023: reported -0.08 11/23 29 Feb 2024: estimate -0.13 29 Feb 2024: reported -0.12 02/24 09 May 2024: estimate -0.11 09 May 2024: reported -0.05 05/24 05 Nov 2024: estimate -0.13 05 Nov 2024: reported -0.06 11/24 27 Feb 2025: estimate -0.35 27 Feb 2025: reported 0.02 02/25 07 May 2025: estimate -0.09 07 May 2025: reported -0.02 05/25 06 Aug 2025: estimate -0.05 06 Aug 2025: reported -0.04 08/25 05 Nov 2025: estimate -0.07 05 Nov 2025: reported -0.07 11/25 26 Feb 2026: estimate -0.03 26 Feb 2026: reported -0.02 02/26 07 May 2026: estimate -0.05 07 May 2026: reported 0.10 05/26 07 Aug 2026: estimate 0.03 07 Aug 2026: reported 0.11 08/26 05 Nov 2026: estimate 0.07 05 Nov 2026: reported 0.09 11/26

Estimate Reported: beat Reported: miss In line

Quarterly results

DateEPS estimateEPS reportedSurpriseResult
25 Feb 2027 08:00 0.12 — — Upcoming
05 Nov 2026 06:00 0.07 0.09 +28.6% Beat
07 Aug 2026 06:00 0.03 0.11 +266.7% Beat
07 May 2026 06:00 -0.05 0.10 +300.0% Beat
26 Feb 2026 06:00 -0.03 -0.02 +31.0% Beat
05 Nov 2025 06:00 -0.07 -0.07 -3.3% Miss
06 Aug 2025 06:00 -0.05 -0.04 +24.2% Beat
07 May 2025 06:00 -0.09 -0.02 +77.8% Beat
27 Feb 2025 06:00 -0.35 0.02 +105.7% Beat
05 Nov 2024 06:00 -0.13 -0.06 +55.5% Beat
06 Aug 2024 07:00 -0.09 — +100.0% —
09 May 2024 06:00 -0.11 -0.05 +53.1% Beat
29 Feb 2024 06:00 -0.13 -0.12 +8.4% Beat
09 Nov 2023 06:00 -0.15 -0.08 +47.4% Beat
09 Aug 2023 07:00 -0.18 -0.08 +56.5% Beat
10 May 2023 06:00 -0.16 -0.11 +29.7% Beat
08 Mar 2023 06:00 -0.08 -0.18 -121.5% Miss
09 Nov 2022 16:00 -0.03 0.02 +158.8% Beat
10 Aug 2022 06:00 0.08 -0.01 -112.4% Miss
12 May 2022 06:00 0.06 0.01 -84.4% Miss
30 Mar 2022 10:00 0.16 0.01 -93.7% Miss
15 Nov 2021 06:00 0.28 0.17 -39.9% Miss
12 Aug 2021 07:00 0.30 0.33 +9.1% Beat
13 May 2021 07:00 0.31 0.27 -14.6% Miss
23 Mar 2021 11:00 0.24 0.33 +40.0% Beat
17 Nov 2020 07:00 0.21 0.04 -81.0% Miss
12 Aug 2020 07:00 0.12 0.06 -49.3% Miss
20 May 2020 07:00 0.11 0.12 +7.6% Beat
08 Apr 2020 07:00 0.11 0.34 +207.1% Beat
18 Nov 2019 17:00 0.13 0.55 +328.0% Beat
14 Aug 2019 17:00 0.12 0.52 +347.0% Beat
28 May 2019 19:00 0.11 0.13 +20.9% Beat
10 Apr 2019 19:00 0.07 0.10 +49.3% Beat
19 Nov 2018 07:00 0.14 0.18 +28.6% Beat

Annual results · USD

YearRevenueChangeNet income Net marginEPSEPS changeFree cash flow
2025 1.2B -0.4% -116.4M -9.9% -0.61 +25.6% 212.3M
2024 1.2B +5.1% -155.1M -13.1% -0.82 +70.6% 123.8M
2023 1.1B -7.3% -526.8M -46.7% -2.79 -113.0% 151M
2022 1.2B — -246.1M -20.2% -1.31 — -170.7M
2021 — — — — — — —

Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.

Prices by day, week and month

Price history in USD, by day
PeriodOpening priceHighLow Closing priceChangeVolumeDividend
03 Mar 2022 20.00 20.31 19.49 19.73 -1.30% 313,000
02 Mar 2022 20.00 20.73 19.79 19.99 -1.24% 289,500
01 Mar 2022 21.00 22.00 20.01 20.24 -5.68% 477,600
28 Feb 2022 21.00 22.05 20.50 21.46 +1.66% 233,100
25 Feb 2022 21.80 22.65 21.06 21.11 -1.72% 788,000
24 Feb 2022 20.50 21.97 19.90 21.48 -0.56% 471,400
23 Feb 2022 22.67 23.00 21.60 21.60 -4.17% 246,500
22 Feb 2022 22.81 23.44 22.20 22.54 -4.97% 464,800
18 Feb 2022 24.34 24.63 23.44 23.72 -3.77% 328,400
17 Feb 2022 25.66 25.72 24.26 24.65 -4.57% 648,600
16 Feb 2022 25.66 26.48 25.31 25.83 -1.03% 309,100
15 Feb 2022 26.50 26.75 25.41 26.10 -0.34% 620,600
14 Feb 2022 26.23 27.08 25.89 26.19 -0.30% 379,700
11 Feb 2022 25.90 27.27 24.83 26.27 +1.19% 550,200
10 Feb 2022 25.25 27.24 24.87 25.96 +2.81% 876,400
09 Feb 2022 23.50 25.27 23.34 25.25 +8.60% 555,500
08 Feb 2022 23.18 23.53 22.25 23.25 +2.42% 320,500
07 Feb 2022 22.00 23.14 21.81 22.70 +3.18% 448,600
04 Feb 2022 20.50 23.18 19.54 22.00 +7.32% 656,500
03 Feb 2022 21.11 22.29 20.41 20.50 -4.96% 255,200
02 Feb 2022 22.16 22.87 21.45 21.57 -1.82% 333,000
01 Feb 2022 20.42 22.00 19.80 21.97 +11.52% 419,400
31 Jan 2022 18.70 20.46 18.50 19.70 +5.69% 622,100
28 Jan 2022 18.88 19.77 18.50 18.64 -1.98% 765,600
27 Jan 2022 19.75 20.27 18.95 19.02 -2.48% 943,100

Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.

News

Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.

Key data

Previous close
10.90 USD
Market cap
2.0B
Exchange
NYSE
Country
United States
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD

Dividends

No dividends on record.

Why this score

How the score is made up
Part of the scorePointsWhy
Business growth Yearly growth of revenue and of earnings per share. 0.0 / 25
  • Revenue growth of -1.0% a year
Quality Return on equity, net margin and how stable the margins are. 0.0 / 25
  • ROE of -46%
Financial strength Net debt against operating earnings, interest cover and free cash flow. 14.2 / 20
  • Net debt is 0.9× EBITDA
  • Free cash flow yield of 7.6%
Valuation Free cash flow yield and the P/E against its sector. 13.0 / 15
  • Forward P/E 19.6: it is expected to earn money
Analysts How far the analysts' average target is from today's price. 10.0 / 10
  • Analysts' target is +57% from the price
  • The last full year was a loss

Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 6 points off.

Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.

Figures

Valuation
FigureValueReading Sector median
P/E (forward) 19.59× Fair 14.89×
Price / book 2.88× Fair 3.8×
Price / sales 1.82× Good 3.19×
EV / EBITDA 7.71× Good 12.61×
Free cash flow yield 7.6% Good 2.5%
Quality
FigureValueReading Sector median
Gross margin 60.6% Good 58.6%
Operating margin 18.4% Good 7.6%
Net margin -41.2% Weak 2.7%
Return on equity -45.6% Weak 5.7%
Return on assets 3.3% Fair 3.5%
Growth
FigureValueReading Sector median
Revenue growth / year -1% Weak 10.8%
Financial health
FigureValueReading Sector median
Debt / equity 0.75× Good 0.48×
Net debt / EBITDA 0.89× Good 1.6×
Interest cover 2.34× Weak 2.65×
Current ratio 5.52× Good 2.36×
Dividends
FigureValueReading Sector median
Payout of earnings 0% Weak 0%

The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.

Follow TRLV and get alerts

Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.

Start for free Log in